{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:18:09Z","timestamp":1781111889842,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104720","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:02:19Z","timestamp":1770253339000},"page":"104720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Treatment patterns and clinical outcomes according to PD-L1 status in &gt;2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results"],"prefix":"10.1016","volume":"86","author":[{"given":"Lazar","family":"Popovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagi S.","family":"El Saghir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitki","family":"Tuzlali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Juozaityt\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Eglitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh C.","family":"Doval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisan","family":"Zirtiloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6tz","family":"Hartleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regula","family":"Deurloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Estaytieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enya","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"D\u2019Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104720_bib1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104720_bib2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib4","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib5","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104720_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/diagnostics10090704","article-title":"Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a systematic review and meta-analysis study","volume":"10","author":"Lotfinejad","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.breast.2026.104720_bib10","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-19-1131","article-title":"Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data","volume":"25","author":"Matikas","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104720_bib11","article-title":"Prognostic value of programmed cell death ligand-1 expression in breast cancer: a meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2026.104720_bib12","doi-asserted-by":"crossref","first-page":"S1145","DOI":"10.1016\/j.annonc.2020.08.2241","article-title":"Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial","volume":"31","author":"Bianchini","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/his.70091","article-title":"Real-world prevalence of PD-L1 positivity in early-stage\/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study","author":"D\u2019Arrigo","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2026.104720_bib14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2026.104720_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.breast.2026.104720_bib17","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2217\/fon-2021-0530","article-title":"Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer","volume":"17","author":"Haiderali","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.farma.2024.03.014","article-title":"Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population","volume":"48","author":"Galindo Garc\u00eda","year":"2024","journal-title":"Farm Hosp"},{"key":"10.1016\/j.breast.2026.104720_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.867583","article-title":"Chemotherapy decision-making and survival outcomes in older women with early triple-negative breast cancer: evidence from real-world practice","volume":"12","author":"Xiu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant atezolizumab for early triple-negative breast cancer: the ALEXANDRA\/IMpassion030 randomized clinical trial","volume":"333","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2026.104720_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib24","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104720_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib27","doi-asserted-by":"crossref","first-page":"GS3","DOI":"10.1158\/1557-3265.SABCS24-GS3-05","article-title":"NSABP B-59\/GBG-96-GeparDouze. A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with stage II and III triple-negative breast cancer","volume":"31","author":"Geyer","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104720_bib28","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib29","doi-asserted-by":"crossref","first-page":"oyaf034","DOI":"10.1093\/oncolo\/oyaf034","article-title":"Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States","volume":"30","author":"Punie","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104720_bib30","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104720_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-021-06193-9","article-title":"Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer","volume":"188","author":"Ahn","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104720_bib32","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.3390\/jcm11195524","article-title":"PD-L1-positive high-grade triple-negative breast cancer patients respond better to standard neoadjuvant treatment \u2013 a retrospective study of PD-L1 expression in relation to different clinicopathological parameters","volume":"11","author":"Stanowska","year":"2022","journal-title":"J Clin Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:29:36Z","timestamp":1775683776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["S0960977626000305"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104720","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104720"}}